Baird analyst Joel Beatty initiated coverage of Pliant Therapeutics with an Outperform rating and $44 price target. The analyst contends that bexotegrast is a promising agent for idiopathic pulmonary fibrosis, supported by the 12-week phase 2a data released by Pliant in January 2023. The firm also believes that the stock will be trading slightly higher upon the release of phase 2a 320mg 24-week data, which is expected "imminently" in Q2 of 2023.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PLRX:
- Pliant Therapeutics to Participate in the 22nd Annual Needham Healthcare Conference
- 3 Best Stocks to Buy Now, 3/28/2023, According to Top Analysts
- Pliant Therapeutics Announces Poster Presentations at the 2023 American Thoracic Society International Conference
- Pliant Therapeutics price target raised to $54 from $53 at H.C. Wainwright
- Pliant Therapeutics price target lowered to $50 from $55 at Citi
